DRDO release guidelines for usage of 2-DG medicine
Total Views |
New Delhi, June 01: Defence Research and Development Organisation (DRDO) on Tuesday released the guidelines for the usage of anti-Covid medicine 2-Deoxy-d-glucose (2-DG) medicine as per DCGI approval. In the guidelines, DRDO has advised that anti-COVID drug 2DG can now be given to COVID-19 patients under the care and prescription of doctors.
In the guidelines DRDO has further added that 2DG should be prescribed as early as possible by doctors for moderate to severe COVID patients for a maximum duration of up to 10 days. DRDO has warned that 2DG should not be given to pregnant and lactating women and patients below 18 years.
The DRDO also asked patients and attendants in need of the 2-DG drug to request the hospital to contact Dr. Reddy’s Lab, Hyderabad for emergency medicine supply. “Patients/Attendants are advised to request their hospital to contact Dr. Reddy’s Lab, Hyderabad for medicine supply at email: 2DG@drreddys.com,” the notice read.
The drug was launched last month by the Ministry of Defence. It has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of the DRDO, in collaboration with Dr. Reddy's Laboratories (DRL) in Hyderabad. The oral drug for emergency use is an adjunct therapy to treat severe Covid patients. It reduces dependence on supplemental oxygen.
.
.